J. Robert Paulson and Jeffrey Mathiesen Appointed to Sun BioPharma Board of Directors

MINNEAPOLIS, MN--(Marketwired - Sep 30, 2015) - Sun BioPharma, Inc., (OTC PINK: SNBP), a biopharmaceutical company developing therapies for pancreatic diseases, today announced the appointment of healthcare executives J. Robert Paulson and Jeffrey Mathiesen to the Company's Board of Directors. The appointments are effective immediately and bring the number of directors to 8 members, of which 4 are independent. 

"The expansion of Sun's board of directors is part of the Company's effort to emphasize our commitment and accountability to shareholders and proper corporate governance practices," said Dr. Michael T. Cullen, Executive Chairman of Sun BioPharma. "Bob's leadership and operational experience in the healthcare field coupled with Jeff's international, capital markets and financial management acumen make them highly qualified to be members of our board. We look forward to their contributions and guidance as we begin the Phase 1 clinical study for our lead development candidate, SBP-101, in Australia which we hope to initiate before the end of this year."

J. Robert Paulson currently serves as President and CEO of NxThera Inc., a Maple Grove, MN based medical device company pioneering the application of its Convective Water Vapor Energy (WAVE™) platform technology to treat endourological conditions. Previously, Mr. Paulson was president, chief executive officer and a director of Restore Medical from 2005 until the company's acquisition by Medtronic in July of 2008 and served as the chief financial officer and vice president of global marketing for Endocardial Solutions, which was acquired by St. Jude Medical in 2005. Mr. Paulson received a JD from Vanderbilt University School of Law, MBA from the University of St. Thomas, and BA from Luther College.

Jeffrey Mathiesen is Chief Financial Officer of Gemphire Therapeutics Inc., a Northville, MI based biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia. Prior to joining Gemphire Therapeutics, Mr. Mathiesen served as CFO of Sunshine Heart, Inc., leading the medical device company through its transition from the Australian capital markets to the U.S., which included a successful IPO and equity financings totaling approximately $100 million. Mr. Mathiesen has more than 20 years of experience as CFO of publicly traded companies, including two successful initial public offerings, encompassing a variety of highly competitive, technology based industries in organizations with global reach. Mr. Mathiesen graduated summa cum laude in Accounting from the University of South Dakota.